Study Offers Potential New Targets for Novel Anti-HIV Drugs

A new study has found that the human immunodeficiency virus (HIV), the cause of AIDS, makes use of the base excision repair pathway when inserting its DNA into the host-cell genome.

Researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, carried out the study.

AIDS/HIV Treatment - Drugs - Proteas Inhibitors - NRTIs - NNRTIs
Encyclopedia section of medindia explains in brief about the treatment for AIDS/HIV

Crippling the repair pathway prevents the virus from completing this critical step in the retrovirus's life cycle.

The findings offer potential new targets for novel anti-HIV drugs that may not lead as quickly to viral resistance as current drugs, the researchers said.

"HIV continues to develop resistance to current therapies," said first author Kristine Yoder, assistant professor of molecular virology, immunology and medical genetics.

Contraceptive Vaginal Rings May Take on an Anti-HIV Role
A flexible ring containing two anti-HIV drugs showed in laboratory tests that it can deliver therapeutic levels of both drugs for up to 30 days, researchers

"But the proteins we talk about in this paper are made by the cell, so drugs that target them might not lead to resistance as quickly as drugs that target viral proteins. And while targeting host proteins does have the potential for side effects, studies of mice suggest that targeting some of these genes may not lead to significant side effects."

Cells normally use base excision repair to fix oxidative damage to DNA caused by reactive molecules such as hydrogen peroxide and oxygen radicals, which form during energy production and other metabolic processes.

Anti-HIV Gel Did Not Prove Itself During Human Trials
An anti-HIV vaginal gel did not meet expectations during human trials.

For this study, Yoder and her colleagues investigated the role of the repair pathway in the virus insertion process by engineering four strains of mouse fibroblast cells that each lacked a component of the pathway. Specifically, they deleted genes for three glycosylase enzymes - Ogg1, Myh, and Neil1 - and one polymerase gene, Pol-beta.

They found that the loss of any of these elements reduced the ability of HIV DNA to integrate with host-cell DNA by about 60 to 70 percent. In an additional experiment, the researchers restored the polymerase in cells that lacked it, and this enabled the HIV DNA to again integrate at its normal level.

New Discovery may Help Create Less Toxic Anti-HIV Drugs
Scientists from The University of Texas at Austin have unravelled the atomic structure of a key human enzyme - a finding that would help create less toxic anti-HIV drugs.

"Overall, our findings indicate that HIV infection and integration efficiency depends on the presence of base excision repair proteins, and that these proteins might make novel new targets for the treatment of HIV infection," Yoder says.

The study has been published in the journal PLoS ONE.

Source-ANI